Alex Bankovich, Ph.D. is Vice President of Research and Development at Link Cell Therapies. Following his academic training, Alex joined Stemcentrx in 2010 as the staff biochemist and biophysicist support antibody discovery. Alex helped build and lead a pipeline assessing the therapeutic viability of 150 novel targets in multiple solid tumor indications with antibody drug conjugates. Following the acquisition of Stemcentrx by AbbVie in 2016, Alex coordinated multi-functional and cross-site collaborations on diverse oncology initiatives. He held a leadership role in antibody drug conjugate development from target selection through early clinical studies.
Alex obtained his B.S. in Chemistry (Biochemistry specialization) Cum laude from The University of Virginia. He obtained his Ph.D. from Stanford University, working in the laboratory of K. Chris Garcia on the structure biology of adaptive immune receptors and cytokines. He then pursued post-doctoral work with Jason Cyster on S1P receptor biology and biochemical interaction with CD69.
Alex has co-authored 25 scientific publications and is an inventor on 3 patents.
